Who are HCP1004's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HGP1408, HCP1105, ASP1585, HGP0816, HCP0910, HCP1102.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hcp1004.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

HCP1004 — Competitive Intelligence Brief

HCP1004 (HCP1004) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor degrader (SARD). Area: Oncology.

phase 3 Androgen receptor degrader (SARD) Androgen receptor (AR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HCP1004 (HCP1004) — Hanmi Pharmaceutical Company Limited. HCP1004 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HCP1004 TARGET	HCP1004	Hanmi Pharmaceutical Company Limited	phase 3	Androgen receptor degrader (SARD)	Androgen receptor (AR)
HGP1408	HGP1408	Hanmi Pharmaceutical Company Limited	phase 3	Androgen receptor degrader (SARD)	Androgen receptor (AR)
HCP1105	HCP1105	Hanmi Pharmaceutical Company Limited	phase 3	Androgen receptor degrader (SARD)	Androgen receptor (AR)
ASP1585	ASP1585	Astellas Pharma Inc	phase 3	Androgen receptor degrader (SARD)	Androgen receptor (AR)
HGP0816	HGP0816	Hanmi Pharmaceutical Company Limited	phase 3	Androgen receptor degrader (SARD)	Androgen receptor (AR)
HCP0910	HCP0910	Hanmi Pharmaceutical Company Limited	phase 3	Androgen receptor degrader (SARD)	Androgen receptor (AR)
HCP1102	HCP1102	Hanmi Pharmaceutical Company Limited	phase 3	Androgen receptor degrader (SARD)	Androgen receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor degrader (SARD) class)

Hanmi Pharmaceutical Company Limited · 8 drugs in this class
Astellas Pharma Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HCP1004 — Competitive Intelligence Brief. https://druglandscape.com/ci/hcp1004. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab